Hui‐Ling Zhen - Publications, H-index & Citations

Hui‐Ling Zhen

incyte

30H指数

166论文数

4.5K被引数

收录论文 34

发表时间

Large circuit models: opportunities and challenges (vol 67, 200402, 2024)

SCIENCE CHINA-INFORMATION SCIENCES

IF7.6

2024-10-21

OAAI

Chen, Lei; Chen, Yiqi; Chu, Zhufei; Fang, Wenji; Ho, Tsung-Yi; Huang, Ru; Huang, Yu; Khan, Sadaf; Li, Min; Li, Xingquan; Li, Yu; Liang, Yun; Liu, Jinwei; Liu, Yi; Lin, Yibo; Luo, Guojie; Pan, Hongyang; Shi, Zhengyuan; Sun, Guangyu; Tsaras, Dimitrios; Wang, Runsheng; Wang, Ziyi; Wei, Xinming; Xie, Zhiyao; Xu, Qiang; Xue, Chenhao; Yan, Junchi; Yang, Jun; Yu, Bei; Yuan, Mingxuan; Young, Evangeline F. Y.; Zeng, Xuan; Zhang, Haoyi; Zhang, Zuodong; Zhao, Yuxiang; Zhen, Hui-Ling; Zheng, Ziyang; Zhu, Binwu; Zhu, Keren; Zou, Sunan

Enhanced machine learning models for predicting one-year mortality in individuals suffering from type A aortic dissection 针对A型主动脉夹层患者一年死亡风险预测的增强型机器学习模型

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

IF4.4

2024-09-01

PREAI

Zhang, Jing; Xiong, Wuyu; Yang, Jiajuan; Sang, Ye; Zhen, Huiling; Tan, Caiwei; Huang, Cuiyuan; She, Jin; Liu, Li; Li, Wenqiang; Wang, Wei; Zhang, Songlin

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 pemigatinib在胆管癌中的开放标签研究: 202的最终结果

ESMO OPEN

IF8.3

2024-06-01

OAAI

Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G. M.; Melisi, D.; Al Rajabi, R. M.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; Oh, D. -Y.; Dotan, E.; V. Catenacci, D.; Van Cutsem, E.; Lihou, C. F.; Zhen, H.; Veronese, M. L.; Abou-Alfa, G. K.

Machine Learning Methods in Solving the Boolean Satisfiability Problem

MACHINE INTELLIGENCE RESEARCH

IF8.7

2023-06-01

PREAI

Guo, Wenxuan; Zhen, Hui-Ling; Li, Xijun; Luo, Wanqian; Yuan, Mingxuan; Jin, Yaohui; Yan, Junchi

A survey for solving mixed integer programming via machine learning 通过机器学习解决混合整数规划的调查

NEUROCOMPUTING

IF6.5

2023-01-01

OAAI

Zhang, Jiayi; Liu, Chang; Li, Xijun; Zhen, Hui-Ling; Yuan, Mingxuan; Li, Yawen; Yan, Junchi

Multiobjective Optimization-Aided Decision-Making System for Large-Scale Manufacturing Planning

IEEE TRANSACTIONS ON CYBERNETICS

IF10.5

2022-08-01

PREAI

Wang, Zhenkun; Zhen, Hui-Ling; Deng, Jingda; Zhang, Qingfu; Li, Xijun; Yuan, Mingxuan; Zeng, Jia

Bilevel learning for large-scale flexible flow shop scheduling

COMPUTERS & INDUSTRIAL ENGINEERING

IF6.5

2022-06-01

PREAI

Li, Longkang; Fu, Xiaojin; Zhen, Hui-Ling; Yuan, Mingxuan; Wang, Jun; Lu, Jiawen; Tong, Xialiang; Zeng, Jia; Schnieders, Dirk

Learning to select cuts for efficient mixed-integer programming

PATTERN RECOGNITION

IF7.6

2022-03-01

OAAI

Huang, Zeren; Wang, Kerong; Liu, Furui; Zhen, Hui-Ling; Zhang, Weinan; Yuan, Mingxuan; Hao, Jianye; Yu, Yong; Wang, Jun

FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine plus cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

ANNALS OF ONCOLOGY

IF65.4

2021-07-01

OAAI

Bekaii-Saab, T.; Valle, J.; Van Cutsem, E.; Rimassa, L.; Furuse, J.; Ioka, T.; Macarulla, T.; Bridgewater, J.; Wasan, H.; Borad, M.; Vogel, A.; Lihou, C.; Zhen, H.; Jiang, P.; Langmuir, P.; Melisi, D.

Accelerate the optimization of large-scale manufacturing planning using game theory

COMPLEX & INTELLIGENT SYSTEMS

IF4.6

2021-04-09

OAAI

Zhen, Hui-Ling; Wang, Zhenkun; Li, Xijun; Zhang, Qingfu; Yuan, Mingxuan; Zeng, Jia

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib FGFR2-Rearranged胆管癌的临床基因组分析确定了对Pemigatinib的反应和耐药机制的相关性

CANCER DISCOVERY

IF33.3

2021-02-02

186

OAAI

Silverman, Ian M.; Hollebecque, Antoine; Friboulet, Luc; Owens, Sherry; Newton, Robert C.; Zhen, Huiling; Feliz, Luis; Zecchetto, Camilla; Melisi, Davide; Burn, Timothy C.

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements FIGHT-302: 一线pemigatinib与吉西他滨联合顺铂治疗FGFR2重排的晚期胆管癌

FUTURE ONCOLOGY

IF2.6

2020-07-17

127

OAAI

Bekaii-Saab, Tanios S.; Valle, Juan W.; Van Cutsem, Eric; Rimassa, Lorenza; Furuse, Junji; Ioka, Tatsuya; Melisi, Davide; Macarulla, Teresa; Bridgewater, John; Wasan, Harpreet; Borad, Mitesh J.; Abou-Alfa, Ghassan K.; Jiang, Ping; Lihou, Christine F.; Zhen, Huiling; Asatiani, Ekaterine; Feliz, Luis; Vogel, Arndt

Fast Covariance Matrix Adaptation for Large-Scale Black-Box Optimization

IEEE TRANSACTIONS ON CYBERNETICS

IF10.5

2020-05-01

PREAI

Li, Zhenhua; Zhang, Qingfu; Lin, Xi; Zhen, Hui-Ling

FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-01

PREAI

Subbiah, Vivek; Barve, Minal; Iannotti, Nicholas O.; Gutierrez, Martin; Smith, David C.; Roychowdhury, Sameek; Papadopoulos, Kyriakos P.; Mettu, Niharika; Edenfield, William J.; Morgensztern, Daniel; Feliz, Luis; Lihou, Christine; Zhen, Huiling; Saleh, Mansoor

FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-01

PREAI

Feliz, Luis; Asatiani, Ekaterine; Lihou, Christine; Zhen, Huiling; Silverman, Ian; Ahnert, Jordi Rodon

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation

CLINICAL LUNG CANCER

IF3.3

2018-09-01

PREAI

Giaccone, Giuscppe; Sanborn, Rachel E.; Wagar, Saiama N.; Martinez-Marti, Alex; Ponce, Santiago; Zhen, Huiling; Kennealey, Gerard; Erickson-Viitanen, Susan; Schaefer, Eric

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

ANNALS OF HEMATOLOGY

IF2.4

2018-02-02

PREAI

Kiladjian, Jean-Jacques; Guglielmelli, Paola; Griesshammer, Martin; Saydam, Guray; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Jones, Mark; Zhen, Huiling; Li, Jingjin; Gadbaw, Brian; Ronco, Julian Perez; Khan, Mahmudul; Verstovsek, Srdan

Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies

MOLECULAR CANCER THERAPEUTICS

IF5.5

2018-01-01

PREAI

Saleh, Mansoor; Gutierrez, Martin; Subbiah, Vivek; Smith, David C.; Feliz, Luis; Zhen, Huiling; Ji, Tao; Nemunaitis, John

Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Verstovsek, Srdan; Rambaldi, Alessandro; Asatiani, Ekaterine; Lihou, Christine F.; Zhen, Huiling; Hochhaus, Andreas